CO5690564A2 - Medicamento para tratar tejido de miocardio infartado que comprende mioblastos oseos de mamiferos geneticamente modoficados para expresar la proteina sdf-1 de mamifero - Google Patents

Medicamento para tratar tejido de miocardio infartado que comprende mioblastos oseos de mamiferos geneticamente modoficados para expresar la proteina sdf-1 de mamifero

Info

Publication number
CO5690564A2
CO5690564A2 CO05015803A CO05015803A CO5690564A2 CO 5690564 A2 CO5690564 A2 CO 5690564A2 CO 05015803 A CO05015803 A CO 05015803A CO 05015803 A CO05015803 A CO 05015803A CO 5690564 A2 CO5690564 A2 CO 5690564A2
Authority
CO
Colombia
Prior art keywords
myocardial tissue
protein
sdf
express
treatment
Prior art date
Application number
CO05015803A
Other languages
English (en)
Inventor
Marc S Penn
Arman T Askari
Matthew Kiedrowski
Original Assignee
Cleveland Clinic Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cleveland Clinic Foundation filed Critical Cleveland Clinic Foundation
Publication of CO5690564A2 publication Critical patent/CO5690564A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/522—Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4, KC
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0375—Animal model for cardiovascular diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

1.- El uso de un agente en la preparación de un medicamento para el tratamiento de tejido de miocardio infartado, El tejido de miocardio infartado que incluye una primera concentración de proteína SDF-1,el medicamento que es adecuado para incrementar la concentración de proteína SDF-1 en el tejido de miocardio infartado desde la primera concentración hacia la segunda concentración.2.- El medicamento de la reivindicación 1 que comprende mioblastos óseos de mamíferos modificados para expresar la proteína SDF-1 mamíferos.3.- El medicamento de la reivindicación 2, el mioblasto óseo que es genéticamente modificado con un vector de expresión, el vector de expresión incluye un ácido nucleico que codifica la proteína SDF-1 de mamíferos.4.- El medicamento de la reivindicación 3, el vector de expresión que comprende un vector viral derivado de al menos un adenovirus, virus asociado con adenovirus, virusde herpes simple, o retrovirus.
CO05015803A 2002-08-22 2005-02-21 Medicamento para tratar tejido de miocardio infartado que comprende mioblastos oseos de mamiferos geneticamente modoficados para expresar la proteina sdf-1 de mamifero CO5690564A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40527402P 2002-08-22 2002-08-22
US10/426,712 US20040037811A1 (en) 2002-08-22 2003-04-30 Stromal cell-derived factor-1 mediates stem cell homing and tissue regeneration in ischemic cardiomyopathy

Publications (1)

Publication Number Publication Date
CO5690564A2 true CO5690564A2 (es) 2006-10-31

Family

ID=31891492

Family Applications (1)

Application Number Title Priority Date Filing Date
CO05015803A CO5690564A2 (es) 2002-08-22 2005-02-21 Medicamento para tratar tejido de miocardio infartado que comprende mioblastos oseos de mamiferos geneticamente modoficados para expresar la proteina sdf-1 de mamifero

Country Status (8)

Country Link
US (1) US20040037811A1 (es)
EP (2) EP2520302B1 (es)
JP (1) JP4280708B2 (es)
AU (1) AU2003268131A1 (es)
BR (1) BRPI0313987A8 (es)
CA (1) CA2504019C (es)
CO (1) CO5690564A2 (es)
WO (1) WO2004017978A1 (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8147824B2 (en) 1999-08-05 2012-04-03 Athersys, Inc. Immunomodulatory properties of multipotent adult progenitor cells and uses thereof
US9694038B2 (en) 2000-04-06 2017-07-04 Wayne P. Franco Combination growth factor therapy and cell therapy for treatment of acute and chronic diseases of the organs
US20050277576A1 (en) * 2000-04-06 2005-12-15 Franco Wayne P Combination growth factor therapy and cell therapy for treatment of acute and chronic diseases of the organs
US20070111935A1 (en) * 2000-04-06 2007-05-17 Franco Wayne P Combination growth factor therapy and cell therapy for treatment of acute and chronic diseases of the organs
US10281478B2 (en) 2000-04-06 2019-05-07 Wayne P. Franco Combination growth factor therapy and cell therapy for treatment of acute and chronic diseases of the organs
US20050271639A1 (en) * 2002-08-22 2005-12-08 Penn Marc S Genetically engineered cells for therapeutic applications
AU2003290601A1 (en) * 2002-11-05 2004-06-03 The Brigham And Women's Hospital, Inc. Mesenchymal stem cells and methods of use thereof
ATE551066T1 (de) * 2004-06-21 2012-04-15 Cleveland Clinic Foundation Ccr-liganden für stammzellen-homing
US20080253996A1 (en) * 2005-10-31 2008-10-16 Laboratories Serono Sa Use of Sdf-1 for the Treatment and/or Prevention of Neurological Diseases
US10117900B2 (en) 2005-11-09 2018-11-06 Athersys, Inc. MAPC treatment of brain injuries and diseases
US11000546B2 (en) 2005-11-09 2021-05-11 Athersys, Inc. Immunomodulatory properties of MAPCs and uses thereof
NZ727755A (en) * 2006-01-23 2023-01-27 Abt Holding Co Mapc therapeutics without adjunctive immunosuppressive treatment
US7696309B2 (en) * 2006-10-23 2010-04-13 The Brigham And Women's Hospital, Inc. Protease resistant mutants of stromal cell derived factor-1 in the repair of tissue damage
ES2520044T3 (es) 2007-03-30 2014-11-11 The Cleveland Clinic Foundation SDF-1 para su uso en el tratamiento de trastornos vasculares periféricos isquémicos
WO2009079451A2 (en) 2007-12-14 2009-06-25 The Cleveland Clinic Foundation Compositions and methods of promoting wound healing
CA2772610C (en) 2009-08-28 2018-01-23 The Cleveland Clinic Foundation Sdf-1 delivery for treating ischemic tissue
US9308277B2 (en) 2010-02-25 2016-04-12 Mesoblast International Sàrl Protease-resistant mutants of stromal cell derived factor-1 in the repair of tissue damage
WO2011121036A2 (en) * 2010-03-30 2011-10-06 Vib Vzw Induction of arteriogenesis using specific factors or by cell therapy with polarized myeloid cells
WO2012048298A2 (en) 2010-10-08 2012-04-12 Caridianbct, Inc. Methods and systems of growing and harvesting cells in a hollow fiber bioreactor system with control conditions
WO2012094512A2 (en) * 2011-01-05 2012-07-12 The Cleveland Clinic Foundation Myocardial tissue targeting peptides
WO2012170495A1 (en) 2011-06-07 2012-12-13 Provasculon, Inc. Methods for repairing tissue damage using protease-resistant mutants of stromal cell derived factor-1
US9617506B2 (en) 2013-11-16 2017-04-11 Terumo Bct, Inc. Expanding cells in a bioreactor
US11008547B2 (en) 2014-03-25 2021-05-18 Terumo Bct, Inc. Passive replacement of media
RU2557385C1 (ru) * 2014-06-18 2015-07-20 Общество с ограниченной ответственностью "НекстГен" Кодон-оптимизированные последовательности и фармацевтическая композиция для восстановления кровеносных сосудов
JP6830059B2 (ja) 2014-09-26 2021-02-17 テルモ ビーシーティー、インコーポレーテッド スケジュール化された細胞フィーディング
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
US10988731B2 (en) 2016-04-29 2021-04-27 Hope Biosciences, Llc Formulation for storage, transportation, and delivery of protein rich conditioned medium
US10513689B2 (en) * 2016-04-29 2019-12-24 Hope Biosciences, Llc Culture media for multipotent stem cells
US11111480B2 (en) 2016-04-29 2021-09-07 Hope Biosctences, Llc Culture media for multipotent stem cells
US10959425B2 (en) 2016-04-29 2021-03-30 Hope Biosciences, Llc Method of banking stem cells
US11965175B2 (en) 2016-05-25 2024-04-23 Terumo Bct, Inc. Cell expansion
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
CN117247899A (zh) 2017-03-31 2023-12-19 泰尔茂比司特公司 细胞扩增
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3150340B2 (ja) 1990-11-13 2001-03-26 イムネクス コーポレイション 二機能選択可能融合遺伝子
JPH09500783A (ja) 1993-05-21 1997-01-28 ターゲッティッド ジェネティクス コーポレイション シトシンデアミナーゼ（ｃｄ）遺伝子に基づく二機能性選択融合遺伝子
US5602301A (en) * 1993-11-16 1997-02-11 Indiana University Foundation Non-human mammal having a graft and methods of delivering protein to myocardial tissue
JP3961019B2 (ja) * 1995-02-28 2007-08-15 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 遺伝子転移媒介の血管形成療法
US5980887A (en) * 1996-11-08 1999-11-09 St. Elizabeth's Medical Center Of Boston Methods for enhancing angiogenesis with endothelial progenitor cells
SG117417A1 (en) * 1998-02-06 2005-12-29 Collateral Therpeutics Inc Variants of the angiogenic factor vascular endothelial cell growth factor: vegf
JP2002506008A (ja) * 1998-03-09 2002-02-26 セント エリザベス メディカル センター 血管新生を調整するための組成物及び方法
US6358697B2 (en) * 1999-04-21 2002-03-19 Children's Hospital Medical Center Intracellular pharmaceutical targeting
US20020061587A1 (en) * 2000-07-31 2002-05-23 Piero Anversa Methods and compositions for the repair and/or regeneration of damaged myocardium

Also Published As

Publication number Publication date
EP1542701A1 (en) 2005-06-22
BRPI0313987A2 (pt) 2017-10-10
EP1542701A4 (en) 2009-11-25
EP2520302A1 (en) 2012-11-07
JP4280708B2 (ja) 2009-06-17
JP2006507244A (ja) 2006-03-02
EP1542701B1 (en) 2012-07-18
EP2520302B1 (en) 2016-08-17
BRPI0313987A8 (pt) 2018-04-24
US20040037811A1 (en) 2004-02-26
AU2003268131A1 (en) 2004-03-11
CA2504019C (en) 2015-06-02
CA2504019A1 (en) 2004-03-04
WO2004017978A1 (en) 2004-03-04

Similar Documents

Publication Publication Date Title
CO5690564A2 (es) Medicamento para tratar tejido de miocardio infartado que comprende mioblastos oseos de mamiferos geneticamente modoficados para expresar la proteina sdf-1 de mamifero
ES2167365T3 (es) Vectores adenovirales de origen animal y utilizacion en terapia genica.
AR020048A1 (es) Un polipeptido dependiente de la vitamina k, una composicion farmaceutica que lo comprende, el uso del mismo para la manufactura de un medicamento, unacido nucleico aislado que codifica a dicho polipeptido y una celula hospedante de mamifero.
BR9712518A (pt) Polipeptìdeo, molécula de dna, vetor de expressão, célula hospedeira, composição farmacêutica, vacina, proteìna de fusão, processo para detectar tuberculose em um paciente, e, kit diagnóstico
PT693924E (pt) Processos para administracao (in vivo) de substancias biologicas e composicoes utilizadas nestes processos
BR0009537A (pt) Composições para tratamento e diagnóstico de câncer de mama e métodos para seu uso
AR012540A1 (es) COMPOSICIoN FARMACÉUTICA LIOFILIZADA DE ANTICUERPOS MONOCLONALES O POLICLONALES, PROCEDIMIENTO PARA SU PRODUCCIoN
BR9815551A (pt) Vacina de envoltório dimérica recombinante contra infecção flaviviral
BR9912653A (pt) Vìrus de herpes atenuado, cepa de vìrus, célula dendrìtica, processo para produzir um célula, composição farmacêutica, uso de um vìrus, e, processo para executar a terapia de gene em um paciente humano ou animal ou para tratar ou prevenir uma infecção patogênica ou câncer para tratar paciente animal
PT915910E (pt) Analogos de exendina, processos para a sua preparacao e medicamentos que os contem
SV2004001556A (es) Preparaciones acidas de insulina con establidad mejorada
ES2190244T3 (es) Uso de la hormona paratiroidea constituida por una secuencia de aminoacidos 1-34 de la hormona paratiroidea humana para reducir el riesco de fracturas oseas vertebrales y no vertebrales.
BR9907189A (pt) Produtos da fração lipìdica do carotenóide de pepino do mar e métodos de uso
BR0110091A (pt) Composições e processos para terapia e diagnóstico de câncer de mama
PE20000939A1 (es) Formulaciones de fsh y variantes de fsh, productos y metodos
AR003589A1 (es) Utilizacion de una cantidad eficaz de al menos un peptido en una composicion cosmetica o para la preparacion de un medicamento destinada paratratar la inflamacion, y un procedimiento de tratamiento cosmetico mediante una composicion cosmetica que contiene a dicho peptido.
ATE50260T1 (de) Purinderivate, verfahren zu ihrer herstellung und pharmazeutische zubereitung.
PT1035844E (pt) Utilizacao de poliois no combate a infeccoes por leveduras e preparacoes de poliol para a referida utilizacao
BR0208041A (pt) Interferon beta modificado com imunogenicidade reduzida
BR0012919A (pt) Vacina para uso na profilaxia e/ou no tratamento da sìndrome de ponto branco (white spot syndrome) em crustáceos, proteìna estrutural derivada do vìrus da sìndrome de ponto branco, sequência de ácido nucléico, uso de uma proteìna estrutural, composição farmacêutica, anticorpos, vacina ou formulação farmacêutica, e, kit diagnóstico para detecção de wssv
DK183389A (da) Fremgangsmaade til fremstilling af en administrerings- og/eller doseringsform for medicinsk aktive materialer
CA2315277A1 (en) Pharmaceutical compositions containing the long pentraxin ptx3
ES2146214T3 (es) Vacunas para actinobacillus pleuropneumoniae.
BR9813514A (pt) Agente para tratamento de fibras queratìnicas
ES2279257T3 (es) Peptido del antigeno muc-1 para el desencadenamiento de una reaccion inmune frente a celulas tumorales.

Legal Events

Date Code Title Description
FC Application refused